OMER On Other Exchanges
Symbol
Exchange
NASDAQ GM
Munich
London

omeros corp (OMER) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OMEROS CORP (OMER)
\

omeros corp (OMER) Related Bloomberg News

View More Bloomberg News

omeros corp (OMER) Related Businessweek News

No Related Businessweek News Found

omeros corp (OMER) Details

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company’s clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PDE10 (OMS824) which is in Phase II clinical trial for treating Huntington's disease and schizophrenia; PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company’s preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is based in Seattle, Washington.

236 Employees
Last Reported Date: 03/1/19
Founded in 1994

omeros corp (OMER) Top Compensated Officers

Co-Founder, Chairman, CEO & President
Total Annual Compensation: $1.5M
Chief Accounting Officer, VP of Finance & Tre...
Total Annual Compensation: $428.5K
Vice President of Legal Affairs
Total Annual Compensation: $481.5K
Compensation as of Fiscal Year 2018.
omeros corp
Omeros Corporation to Report Q1, 2019 Results on May 09, 2019

Omeros Corporation announced that they will report Q1, 2019 results at 5:00 PM, Eastern Standard Time on May 09, 2019

Omeros Corporation, Q1 2019 Earnings Call, May 09, 2019

Omeros Corporation, Q1 2019 Earnings Call, May 09, 2019

Omeros Corporation Announces Presentation of OMIDRIA Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting

Omeros Corporation announced that the results of an investigator-sponsored real-world study of its FDA-approved ophthalmic drug OMIDRIA (phenylephrine and ketorolac intraocular solution) 1% /0.3% will be presented at the American Society of Cataract and Refractive Surgery – American Society of Ophthalmic Administrators Annual Meeting to be held in San DiegoMay 3-7, 2019. The presentation by Keith A. Walter, M.D., Professor of Ophthalmology at Wake Forest University School of Medicine, is entitled Rate of Pseudophakic Cystoid Macular Edema Using Intraoperative and Topical NSAIDs Alone Without Steroids. The study compares the incidence of cystoid macular edema, a sight-threatening complication of cataract surgery, in patients undergoing cataract surgery using OMIDRIA with postoperative NSAIDs alone versus those using postoperative corticosteroids, in the absence of OMIDRIA, with and without NSAIDs.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

OMER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMER.
View Industry Companies
 

Industry Analysis

OMER

Industry Average

Valuation OMER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact OMEROS CORP, please visit www.omeros.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.